To search for an exact phrase, add quotes around the phrase.

Showing page 7 of 8 - total 77 results found.

  1. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

    https://clinicaltrials.llu.edu/trials/efficacy-safety-and-pharmacokinetics-...
    This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16. The primary hypothesis is Vericiguat is superior to placebo in reducing NT-proBNP at Week 16. …
  2. Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

    https://clinicaltrials.llu.edu/trials/visionary-study-phase-3-trial-sibepre...
    This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving maximally tolerated standard-of-care therapy. Conditions Immunoglobulin …
  3. Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

    https://clinicaltrials.llu.edu/trials/delivery-sso2-therapy-60-min-anterior...
    A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful reperfusion (via PCI) within 6 hours after onset of symptoms compared to …
  4. Prophylaxis Regimen for Hemophilia A Patients

    https://clinicaltrials.llu.edu/trials/prophylaxis-regimen-hemophilia-patien...
    Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the blood …
  5. Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

    https://clinicaltrials.llu.edu/trials/study-alxn2050-proliferative-lupus-ne...
    This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams \[mg\]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with …
  6. Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

    https://clinicaltrials.llu.edu/trials/assessment-safety-and-efficacy-01-rgn...
    The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK) Conditions Neurotrophic Keratopathy Intervention RGN-259 Placebo Principal Investigator Affeldt, John Sponsor …
  7. Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

    https://clinicaltrials.llu.edu/trials/long-term-follow-study-risdiplam-part...
    A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants …
  8. SELUTION SLR™ 014 In-stent Restenosis

    https://clinicaltrials.llu.edu/trials/selution-slr%E2%84%A2-014-stent-reste...
    Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. …
  9. The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH

    https://clinicaltrials.llu.edu/trials/purpose-study-determine-whether-cereb...
    The primary goal of this study is to assess the occurrence of flushing interventions to address occlusions during the treatment of interventricular hemorrhage (spontaneous primary IVH or secondary IVH due to ruptured aneurysm). Conditions Intraventricular …
  10. INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

    https://clinicaltrials.llu.edu/trials/inhale-3-afrezza%C2%AE-combined-insul...
    INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, …